Evidence map›Paper›PMID 40655603›Full record

ArticleJournal of pharmacy & bioallied sciences2025

Exploring Novel Y140F/H Mutant Fungal CYP51 Inhibitors: A Molecular Docking and Dynamics Study on Thiophene Compounds.

Abdulrahim A Alzain, Alaa Edris, Rua M Mukhtar, Hagar M Mohamed, Malek Abdullah Marzoqi Aldowimar, Ali A Alqarni, Gamal A Mohamed, Sabrin R M Ibrahim

Abstract read
In one paragraph

Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdulrahim A AlzainDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Wad Madani 21111, Sudan.
Alaa EdrisDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Wad Madani 21111, Sudan.
Rua M MukhtarDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Wad Madani 21111, Sudan.
Hagar M MohamedDepartment of Medical Laboratory Analysis, Faculty of Medical and Health Sciences, Liwa University, Abu Dhabi 41009, United Arab of Emirates.
Malek Abdullah Marzoqi AldowimarPrince Mohammed Bin Abdulaziz Hospital-Al Madinah Al Munawarah-NGHA, Ministry of National Guard Health Affairs, Al Madinah Al Munawarah 41511, Saudi Arabia.
Ali A AlqarniDepartment of Pharmaceutical Care, Ministry of National Guard-Health Affairs, Jeddah 22384, Saudi Arabia.
Gamal A MohamedDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Sabrin R M IbrahimDepartment of Chemistry, Preparatory Year Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Invasive fungal infections (IFIs) pose a significant risk specifically to the health of immunocompromised individuals, leading to a substantial number of deaths annually. Therapeutic options for IFIs are limited compared to bacterial infections, with only three classes of antifungal medications currently in use. The widespread use of triazole antifungals for IFI prevention and treatment, along with long treatment durations, has led to the emergence of severe drug resistance, indicating the urgent need for intervention to address this critical issue. This study aims to identify novel inhibitors for the Y140F/H fungal CYP51 enzyme. Methods: Molecular docking and molecular dynamics were utilized to evaluate 161 thiophene compounds for their inhibitory potential against the mutant CYP51. Findings: The docking process involved two stages: docking on the wild type followed by docking on the mutant type, leading to the discovery of three compounds (referred to as compounds 1, 2, and 3) with better docking scores than the reference, indicating stronger binding affinity. Subsequent molecular dynamics simulations demonstrated that these three compounds displayed favorable stability and flexibility characteristics. Conclusion: Based on our findings, we suggest that compounds 1, 2, and 3 have the potential to act as inhibitors of the Y140F/H CYP51 enzyme.

Indexed as

CYP51drug discoveryfungal infectionshealth and well-beingmolecular dockingmolecular dynamicsthiophene

Identifiers

PMID40655603
PMCPMC12244859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.